Elanco Animal Health INC Form 4 insider transactions

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units convertible to common stock or cash.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units on July 12, 2024.

Elanco Animal Health's CEO, Jeffrey Simmons, reported the acquisition of deferred stock units on July 12, 2024.

Grace McArdle, EVP at Elanco Animal Health, disposed of 4,345 shares to cover tax liabilities upon vesting of restricted stock units.

James Meer, Chief Accounting Officer of Elanco Animal Health, reports the disposal of 1,160 shares to cover tax liabilities upon vesting of restricted stock units.

Elanco Animal Health's CEO, Jeffrey Simmons, reported the acquisition of deferred stock units convertible to common stock, according to a Form 4 filing with the SEC.

Director Lawrence Kurzius elected to defer director fees into Elanco Animal Health Inc. stock units.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units on June 28, 2024.

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units convertible to common stock, according to a Form 4 filing with the SEC.

Elanco Animal Health's CEO, Jeffrey N. Simmons, reported the acquisition of deferred stock units on May 31, 2024.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units convertible to common stock or cash.

Director William F. Doyle purchased 15,000 shares of Elanco Animal Health Inc. at $16.98 per share on May 21, 2024.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health Inc, reported the acquisition of deferred stock units convertible to common stock, according to a recent SEC filing.

Elanco Animal Health Inc. CEO Jeffrey N. Simmons acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units on May 3, 2024.

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Elanco Animal Health's CEO, Jeffrey N. Simmons, reported the acquisition of deferred stock units, convertible to common stock, as per a recent SEC Form 4 filing.

Elanco Animal Health's Executive Vice President, Rajeev A. Modi, reports the acquisition of deferred stock units convertible to common stock following termination of employment.

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired deferred stock units convertible to common stock, as reported in a recent SEC filing.

Elanco Animal Health's Executive Vice President, Rajeev A. Modi, reports acquiring deferred stock units convertible to common stock or cash.

Timothy J. Bettington, an Executive Vice President at Elanco Animal Health, disposed of 23,557 shares of common stock on April 3, 2024, to cover tax liabilities related to vesting restricted stock units.

Elanco Animal Health Inc. executive Rajeev A. Modi disposed of 7,509 shares of common stock to cover tax liabilities upon vesting of restricted stock units.

Director Lawrence Kurzius increased his holdings in Elanco Animal Health Inc. through the acquisition of deferred stock units as part of the company's Directors' Deferral Plan.

Elanco Animal Health CEO Jeffrey N. Simmons acquired deferred stock units convertible to common stock, as reported in a recent SEC Form 4 filing.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units convertible to common stock, according to a Form 4 filing with the SEC.

Elanco Animal Health CEO Jeffrey N. Simmons acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Director William F. Doyle purchased 15,000 shares of Elanco Animal Health Inc. on March 8, 2024, at a price of $16.3 per share.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units on March 8, 2024.

Director Michael J. Harrington purchased 3,100 shares of Elanco Animal Health Inc. common stock at a price of $16.2883 per share on March 8, 2024.